GSK Stock Recent News

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

GSK plc (NYSE:GSK ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer David Redfern - President Corporate Development Conference Call Participants James Gordon - JPMorgan James Gordon Good morning.

The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.

Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.

Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.

GSK PLC (LSE:GSK, NYSE:GSK) has announced plans to acquire the US biotech company IDRx for up to $1.15bn, including $1bn upfront, in a bid to expand its portfolio of cancer therapies. The deal includes IDRX-42, a promising drug designed to treat gastrointestinal stromal tumours (GIST), a rare and aggressive form of cancer that develops in the digestive tract.

British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.

PLYMOUTH, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDR.